AbbVie’s Phase 3 Pediatric Constipation Study Completes, Potential Market Impact Looms

Abbvie ((ABBV)) announced an update on their ongoing clinical study.

AbbVie, in collaboration with Ironwood Pharmaceuticals, has completed a Phase 3 study titled A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation. The study aimed to evaluate the safety and efficacy of linaclotide, an oral drug, in treating functional constipation in young children, a condition with no currently approved pharmacological treatments.

The intervention tested was linaclotide, an oral capsule designed to alleviate symptoms of functional constipation in pediatric patients. The study compared linaclotide to a placebo to assess adverse events and changes in disease activity.

This interventional study followed a randomized, sequential model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose was treatment-focused, aiming to provide insights into the drug’s safety and efficacy in a pediatric population.

The study began on December 2, 2022, and the last update was submitted on September 15, 2025. These dates are crucial as they mark the progress and completion of the study, providing a timeline for stakeholders to assess the development and potential market entry of the treatment.

The completion of this study could positively influence AbbVie’s stock performance by potentially introducing a new treatment option for pediatric functional constipation, a market with unmet needs. This development may enhance investor sentiment, especially given the lack of approved pharmacological treatments in this area, positioning AbbVie ahead of competitors in the pediatric gastrointestinal treatment market.

The study has been completed, and further details are available on the ClinicalTrials portal.